Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

Regorafenib significantly prolonged progression-free survival (PFS) in pretreated patients with advanced non-adipocytic sarcoma (HR = 0.46; <i>p</i> < 0.001) in a placebo-controlled, randomized, phase-II trial (NCT01900743). Thus, here, we assessed the prevalence of 57 biomarkers and...

Full description

Bibliographic Details
Main Authors: Thomas Brodowicz, Bernadette Liegl-Atzwanger, Nicolas Penel, Olivier Mir, Jean-Yves Blay, Karl Kashofer, Axel Le Cesne, Emilie Decoupigny, Jennifer Wallet, Rainer Hamacher, Marie-Cecile Le Deley
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
regorafenib
biomarkers
sarcoma
soft tissue sarcoma
prognosis
multikinase inhibitor
Online Access:https://www.mdpi.com/2072-6694/12/12/3746

Internet

https://www.mdpi.com/2072-6694/12/12/3746

Similar Items